Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
NCT05731128Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of dupilumab in ulcerative colitis (UC) (3 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving clinical response at 24 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05731128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731128.